702 related articles for article (PubMed ID: 25269339)
1. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severely recalcitrant chronic spontaneous urticaria: a discussion of relevant issues.
Wieder S; Maurer M; Lebwohl M
Am J Clin Dermatol; 2015 Feb; 16(1):19-26. PubMed ID: 25452254
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
Saini SS; Bindslev-Jensen C; Maurer M; Grob JJ; Bülbül Baskan E; Bradley MS; Canvin J; Rahmaoui A; Georgiou P; Alpan O; Spector S; Rosén K
J Invest Dermatol; 2015 Jan; 135(1):67-75. PubMed ID: 25046337
[TBL] [Abstract][Full Text] [Related]
8. Real-life experiences with omalizumab for the treatment of chronic urticaria.
Sussman G; Hébert J; Barron C; Bian J; Caron-Guay RM; Laflamme S; Stern S
Ann Allergy Asthma Immunol; 2014 Feb; 112(2):170-4. PubMed ID: 24468258
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.
Song CH; Stern S; Giruparajah M; Berlin N; Sussman GL
Ann Allergy Asthma Immunol; 2013 Feb; 110(2):113-7. PubMed ID: 23352531
[TBL] [Abstract][Full Text] [Related]
10. Ligelizumab for Chronic Spontaneous Urticaria.
Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
[TBL] [Abstract][Full Text] [Related]
11. The maddening itch: an approach to chronic urticaria.
Viegas LP; Ferreira MB; Kaplan AP
J Investig Allergol Clin Immunol; 2014; 24(1):1-5. PubMed ID: 24765875
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab in the treatment of chronic urticaria.
Francés L; Leiva-Salinas M; Silvestre JF
Actas Dermosifiliogr; 2014; 105(1):45-52. PubMed ID: 23938072
[TBL] [Abstract][Full Text] [Related]
13. Therapy of chronic urticaria: a simple, modern approach.
Kaplan AP
Ann Allergy Asthma Immunol; 2014 May; 112(5):419-25. PubMed ID: 24656924
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice.
Labrador-Horrillo M; Valero A; Velasco M; Jáuregui I; Sastre J; Bartra J; Silvestre JF; Ortiz de Frutos J; Gimenez-Arnau A; Ferrer M
Expert Opin Biol Ther; 2013 Sep; 13(9):1225-8. PubMed ID: 23875845
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.
Kulthanan K; Tuchinda P; Chularojanamontri L; Likitwattananurak C; Ungaksornpairote C
J Dermatolog Treat; 2017 Mar; 28(2):160-165. PubMed ID: 27388043
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab is efficacious for management of recalcitrant, antihistamine-resistant chronic urticaria.
Lang DM
Drugs Today (Barc); 2015 Jun; 51(6):367-74. PubMed ID: 26261850
[TBL] [Abstract][Full Text] [Related]
18. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria.
Metz M; Ohanyan T; Church MK; Maurer M
JAMA Dermatol; 2014 Mar; 150(3):288-90. PubMed ID: 24477320
[TBL] [Abstract][Full Text] [Related]
19. Biologic agents and the therapy of chronic spontaneous urticaria.
Kaplan AP; Popov TA
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):347-53. PubMed ID: 24936849
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
Har D; Patel S; Khan DA
Ann Allergy Asthma Immunol; 2015 Aug; 115(2):126-9. PubMed ID: 26093778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
